AML patients harboring FMS-like tyrosine kinase-3-internal tandem duplications (FLT3-ITD) exhibit poor outcomes upon treatment with cytarabine- and anthracycline-based induction therapy primarily due to therapy resistance mediated by selective upregulation of Mcl-1. The gene discussed is MCL1; the disease is acute myeloid leukemia.